Discovery and Validation of Novel Protein Biomarkers in Ovarian Cancer Patient Urine
PROTEOMICS - CLINICAL APPLICATIONS2018Vol. 12(3), pp. e1700135–e1700135
Citations Over TimeTop 10% of 2018 papers
Jarrod J. Sandow, Adam Rainczuk, Giuseppe Infusini, Ming Makanji, Maree Bilandzic, Amy L. Wilson, Nicole Fairweather, Peter G. Stanton, Daniel J. Garama, Daniel J. Gough, Thomas W. Jobling, Andrew I. Webb, Andrew N. Stephens
Abstract
This is the first application of a LFQ-PRM workflow to identify and validate ovarian cancer-specific biomarkers in patient urine samples.
Related Papers
- → Regulation of invasion and peritoneal dissemination of ovarian cancer by mesothelin manipulation(2020)54 cited
- The value of mesothelin in the diagnosis and follow-up of surgically treated ovarian cancer.(2013)
- Significace of serum Mesothelin and CA125 in diagnosis of ovarian cancer(2012)
- Mesothelin expression in ovarian cancer and its potential as targeted ovarian cancer immunotherapy(2017)
- → Abstract 1780: Anetumab ravtansine has single-agent activity in mesothelin-expressing human ovarian cancer models and potentiates the activity of chemotherapeutics and targeted agents(2018)